AI assistant
NEKTAR THERAPEUTICS — Director's Dealing 2017
Dec 20, 2017
32134_dirs_2017-12-19_74609c1b-19df-4b0d-82de-1e042721c656.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: NEKTAR THERAPEUTICS (NKTR)
CIK: 0000906709
Period of Report: 2017-12-15
Reporting Person: Thomsen Jillian B. (SVP & Chief Accounting Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2017-12-15 | Common Stock | A | 10400 | $0.00 | Acquired | 71402 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2017-12-15 | Stock Option | $56.90 | A | 26250 | Acquired | 2025-12-14 | Common Stock (26250) | Direct |
Footnotes
F1: This stock award was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive, upon vesting of the unit, one share of the issuer's common stock. These RSUs vest over three years in substantially equal quarterly installments based on continued service.
F2: This number includes 988 shares held by the reporting person in the Issuer's 401(K) plan and 3,703 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c).
F3: This stock option vests over four years in equal monthly installments based on continued service.